Diabetic ketoacidosis (DKA) is a serious complication of relative insulin deficiency affecting primarily type-1 diabetes mellitus (DM). DKA can occur in type-2 DM when insulin levels fall far behind the body’s needs. DKA is so named due to high levels of water-soluble ketone bodies (KBs), leading to an acidotic physiologic state.[1][2]
Produced by the liver during fatty acid metabolism, KBs can be utilized by the brain, cardiac and skeletal muscle tissues as a fuel when the body is deficient in or cannot effectively import glucose.[3][4]
Ketone bodies, while always present in blood, increase to pathologic levels when the body cannot utilize glucose: low blood glucose levels during fasting, starvation, vigorous exercise, or secondary to a defect in the insulin production. In type-2 DM, insulin production may be normal but below the level needed to shunt glucose into cells.[5][6]
Most body fat is stored as triglyceride (TG). When the body glucose storage sites are depleted, the liver dismantles the TG into three fatty acids (FAs) and a glycerol molecule. The FAs are used as a source of energy, while glycerol converts to glucose. In the presence of enough insulin, this glucose will be consumed by the different body tissues as a source of energy. Typically, this is what occurs in the case of starvation, fasting, and vigorous exercise. In the absence of insulin, the body cannot utilize the glucose released from the glycerol metabolism unused glucose rises to dangerous levels, with spillover into the urine.
When the blood glucose is low or cannot be used due to lack of insulin, ketones are the major source of energy for the brain. The brain does not have any fuel stores and has no other non-glucose-derived energy sources.
Muscles are different from the brain in that they have a large store of glycogen. Approximately 70% of the total body glycogen is stored in muscles and can be converted, when needed, to glucose in a process called glycogenolysis.
Ketone bodies, while always present in blood, increase to pathologic levels when the body cannot utilize glucose: low blood glucose levels during fasting, starvation, vigorous exercise, or secondary to a defect in the insulin production. In type-2 DM, insulin production may be normal but below the level needed to shunt glucose into cells.[7]
Most body fat is stored as triglyceride (TG). When the body glucose storage sites are depleted, the liver dismantles the TG into three fatty acids (FAs) and a glycerol molecule. The FAs are used as a source of energy, while glycerol converts to glucose. In the presence of enough insulin, this glucose will be consumed by the different body tissues as a source of energy. This is typically what occurs in the case of starvation, fasting & vigorous exercise. In the absence of insulin, the body cannot utilize the glucose released from the glycerol metabolism unused glucose rises to dangerous levels, with spillover into the urine.
When the blood glucose is low or cannot be used due to lack of insulin, ketones are the major source of energy for the brain. The brain does not have any fuel stores and has no other non-glucose-derived energy sources.
Muscles are different from the brain in that they have a large store of glycogen. Approximately 70% of the total body glycogen is stored in muscles and can be converted, when needed, to glucose in a process called glycogenolysis.
The physiologic disturbance in DKA is due to several interrelated processes:
DM is a chronic illness. Episodes of DKA recur in poorly controlled patients. It is difficult to characterize the precise effect of these repeated episodes, but clearly, a poor HbA1c predicts micro-vascular and macro-vascular complications of diabetes.
In up to 1% of DKA patients, cerebral edema occurs when rapid osmolar shifts occur. Look for signs of sudden increased intracranial pressure: bradycardia, headache, papilledema, irritability, rising blood pressure and decreasing Glasgow coma scale (GCS). Cerebral edema mortally approaches 25%. Survivors suffer significant neurological morbidity.
Three ketone molecules predominate in human physiology: beta-hydroxybutyrate (BHB), acetoacetate, and acetone.
Beta-hydroxybutyrate represents the most precise approach to measuring the severity of DKA, making up roughly 75% of ketones in DKA. Whole blood ketone test strips and serum laboratory tests quantify BHB. Most urine strips test for acetoacetate and acetone.
BHB can be confirmed in the blood up to 24 hours before acetone and acetoacetate appear in the urine, as BHB is converted into these molecules. Therefore, urine ketone testing can increase even after proper DKA treatment ceases the formation of BHB. Acetone, which is stored in adipose tissue, slowly releases in the blood and is excreted in the urine.
Serum ketone levels:
Urine ketone strip levels:
Ill patients with type-1 DM should be evaluated for DKA. DKA could cause the critical symptoms or occur secondarily to another illness. In newly diagnosed diabetic children, there may be a history of polydipsia, polyuria, weight loss, fatigue, lack of concentration, poor school performance, or recurrent infection. Abdominal pain, nausea, and vomiting are also common; some children in the first DKA episode may be misdiagnosed as viral gastroenteritis.
The metabolic acidosis will lead to rapid, deep breathing (Kussmaul respirations). The breath may have a fruity odor due to respiratory acetone elimination. Investigate for underlying causes of the DKA exacerbation: infection, trauma, among others. DKA patients will have an ileus and have vague, diffuse abdominal pain. Dehydration, thirst, and polyuria are common at the time of presentation due to glucosuria and osmotic diuresis.
DKA is definitively diagnosed by blood testing, with metabolic acidosis and typically hyperglycemia. Ketone testing can be helpful but is not necessary. Low serum bicarbonate (below 18 mmol/L) with elevated anion gap (AG) will be present and can obviate the need for blood gas testing. The anion gap is calculated as follows: (Na+K)-(Cl+HCO3). Ketoacids (primarily BHB) are unmeasured ions, leading to the “gap” in anions. The AG is normally between 6 mEq/L to 12 mEq/L, with levels above 15 typically present in DKA.[8][9][10]
BHB is usually above 3 mmol/L in these patients.
If blood gas testing is performed, venous blood will give enough information. A pH below 7.2 is very concerning.
Blood glucose is usually elevated above generally above 200 mg/dL (11 mmol/l) and may be above 1000 mg/dL. The pediatric patient can be in DKA with very slight elevations in blood glucose.
Urinary ketone levels over “three plus” are used to diagnose but not to monitor the treatment.
Usually, blood osmolality is elevated in DKA. Blood osmolality = 2 x (Na+K) + urea + glucose (all in mmol/L). Normal serum range is between 285 mOsm/L to -295 mOsm/L. Calculated plasma osmolality can greatly minimize the true value of DKA. The osmolar gap is the lab measured osmolality minus the calculated osmolality. When the gap exceeds 10, it presents the presence of an excess osmotically active substance as blood glucose.
Treatment for DKA begins with ABCs and fluid resuscitation.Insulin therapy, usually by continuous infusion, can begin once the patient is stabilized.[1][11][12][13]
Recurrent DKA is a particular problem in adolescents and may be fatal. Early help is advised as soon as the DKA diagnosis is made.
It may be precipitated by:
Pediatric diabetic ketoacidosis is a life-threatening disorder that is best managed by an interprofessional team that includes an emergency nurse, an emergency department physician, endocrinologist, an infectious disease expert, pediatrician, and intensivist. These individuals are best managed in the ICU and monitored by nurses. Once hydration and correction of the acidosis have taken place, the cause of the ketoacidosis must be sought. The key is to prevent this disorder from recurring. The primary caregiver and the diabetic nurse must work closely with the caregiver to ensure that the patient is compliant with the insulin.
The outlook for pediatric patients with DKA is guarded. [14][8][15](Level V)
[1] | Abulebda K,Whitfill T,Montgomery EE,Kirby ML,Ahmed RA,Cooper DD,Nitu ME,Auerbach MA,Lutfi R,Abu-Sultaneh S, Improving Pediatric Diabetic Ketoacidosis Management in Community Emergency Departments Using a Simulation-Based Collaborative Improvement Program. Pediatric emergency care. 2019 Mar 12; [PubMed PMID: 30870337] |
[2] | Agarwal HS, Subclinical cerebral edema in diabetic ketoacidosis in children. Clinical case reports. 2019 Feb; [PubMed PMID: 30847186] |
[3] | Flood K,Nour M,Holt T,Cattell V,Krochak C,Inman M, Implementation and Evaluation of a Diabetic Ketoacidosis Order Set in Pediatric Type 1 Diabetes at a Tertiary Care Hospital: A Quality-Improvement Initiative. Canadian journal of diabetes. 2018 Dec 26; [PubMed PMID: 30777707] |
[4] | Danne T,Garg S,Peters AL,Buse JB,Mathieu C,Pettus JH,Alexander CM,Battelino T,Ampudia-Blasco FJ,Bode BW,Cariou B,Close KL,Dandona P,Dutta S,Ferrannini E,Fourlanos S,Grunberger G,Heller SR,Henry RR,Kurian MJ,Kushner JA,Oron T,Parkin CG,Pieber TR,Rodbard HW,Schatz D,Skyler JS,Tamborlane WV,Yokote K,Phillip M, International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes care. 2019 Feb 6; [PubMed PMID: 30728224] |
[5] | Al Zahrani AM,Al Shaikh A, Glycemic Control in Children and Youth With Type 1 Diabetes Mellitus in Saudi Arabia. Clinical medicine insights. Endocrinology and diabetes. 2019; [PubMed PMID: 30718968] |
[6] | Jawaid A,Sohaila A,Mohammad N,Rabbani U, Frequency, clinical characteristics, biochemical findings and outcomes of DKA at the onset of type-1 DM in young children and adolescents living in a developing country - an experience from a pediatric emergency department. Journal of pediatric endocrinology [PubMed PMID: 30699071] |
[7] | Agrawal S,Baird GL,Quintos JB,Reinert SE,Gopalakrishnan G,Boney CM,Topor LS, Pediatric Diabetic Ketoacidosis With Hyperosmolarity: Clinical Characteristics and Outcomes. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018 Aug; [PubMed PMID: 30084686] |
[8] | Glaser N,Kuppermann N, Fluid treatment for children with diabetic ketoacidosis: How do the results of the pediatric emergency care applied research network Fluid Therapies Under Investigation in Diabetic Ketoacidosis (FLUID) Trial change our perspective? Pediatric diabetes. 2019 Feb; [PubMed PMID: 30417497] |
[9] | Abbas Q,Arbab S,Haque AU,Humayun KN, Spectrum of complications of severe DKA in children in pediatric Intensive Care Unit. Pakistan journal of medical sciences. 2018 Jan-Feb; [PubMed PMID: 29643888] |
[10] | Baalaaji M,Jayashree M,Nallasamy K,Singhi S,Bansal A, Predictors and Outcome of Acute Kidney Injury in Children with Diabetic Ketoacidosis. Indian pediatrics. 2018 Apr 15; [PubMed PMID: 29428918] |
[11] | Weinberger K,Seick Barbarini D,Simma B, Adherence to Guidelines in the Treatment of Diabetic Ketoacidosis in Children: An Austrian Survey. Pediatric emergency care. 2018 Jul 24; [PubMed PMID: 30045350] |
[12] | Gunn ER,Albert BB,Hofman PL,Cutfield WS,Gunn AJ,Jefferies CA, Pathways to reduce diabetic ketoacidosis with new onset type 1 diabetes: Evidence from a regional pediatric diabetes center: Auckland, New Zealand, 2010 to 2014. Pediatric diabetes. 2017 Nov; [PubMed PMID: 27726271] |
[13] | Abulebda K,Abu-Sultaneh S,White EE,Kirby ML,Phillips BC,Frye CT,Murphy LD,Lutfi R, Disparities in Adherence to Pediatric Diabetic Ketoacidosis Management Guidelines Across a Spectrum of Emergency Departments in the State of Indiana: An Observational In Situ Simulation-Based Study. Pediatric emergency care. 2018 Apr 24; [PubMed PMID: 29698339] |
[14] | Foster NC,Beck RW,Miller KM,Clements MA,Rickels MR,DiMeglio LA,Maahs DM,Tamborlane WV,Bergenstal R,Smith E,Olson BA,Garg SK, State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes technology [PubMed PMID: 30657336] |
[15] | Sildorf SM,Breinegaard N,Lindkvist EB,Tolstrup JS,Boisen KA,Teilmann GK,Skovgaard AM,Svensson J, Poor Metabolic Control in Children and Adolescents With Type 1 Diabetes and Psychiatric Comorbidity. Diabetes care. 2018 Nov; [PubMed PMID: 30270201] |